LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

Search

Organon & Co

Fermé

SecteurSoins de santé

10.36 -0.96

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.24

Max

10.57

Chiffres clés

By Trading Economics

Revenu

-174M

-87M

Ventes

81M

1.6B

P/E

Moyenne du Secteur

3.502

35.733

BPA

1

Rendement du dividende

9.37

Marge bénéficiaire

-5.443

Employés

10,000

EBITDA

124M

449M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+73.41% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

9.37%

3.13%

Prochains Résultats

30 oct. 2025

Date du Prochain Dividende

11 sept. 2025

Date du Prochain Détachement de Dividende

11 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-65M

2.4B

Ouverture précédente

11.32

Clôture précédente

10.36

Sentiment de l'Actualité

By Acuity

50%

50%

173 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Organon & Co Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 sept. 2025, 23:59 UTC

Acquisitions, Fusions, Rachats

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept. 2025, 22:02 UTC

Principaux Mouvements du Marché

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept. 2025, 17:01 UTC

Principaux Mouvements du Marché

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept. 2025, 17:01 UTC

Principaux Mouvements du Marché

Tron Shares Rise After New Investment From Bravemorning

8 sept. 2025, 16:14 UTC

Principaux Mouvements du Marché

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept. 2025, 16:13 UTC

Principaux Mouvements du Marché

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept. 2025, 21:47 UTC

Principaux Mouvements du Marché

Microsoft Signs $17.4B AI Deal With Nebius

8 sept. 2025, 21:33 UTC

Acquisitions, Fusions, Rachats

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept. 2025, 21:20 UTC

Acquisitions, Fusions, Rachats

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept. 2025, 21:19 UTC

Acquisitions, Fusions, Rachats

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept. 2025, 21:18 UTC

Acquisitions, Fusions, Rachats

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept. 2025, 16:59 UTC

Market Talk
Acquisitions, Fusions, Rachats

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 16:16 UTC

Résultats

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparaison

Variation de prix

Organon & Co prévision

Objectif de Prix

By TipRanks

73.41% hausse

Prévisions sur 12 Mois

Moyen 18 USD  73.41%

Haut 18 USD

Bas 18 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

8.53 / 9.18Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

173 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat